Human isotope fractional absorption studies comparing chelated Magnesium Glycinate vs. Citrate vs. 4% Oxide, CYP2R1/CYP27B1 magnesium-dependent Vitamin D3 activation trials, and Metformin-induced Vitamin B12 holotranscobalamin depletion. Explore 4,327 indexed studies and multi-trial syntheses with verified PubMed PMIDs, participant sample sizes (N), and Absolute vs. Relative Risk numbers.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
Conclusion: MCMs are well suited to modeling long-term survival in acute myeloid leukemia patients.
Future studies are needed to test if an increase in phase angle is linked to clinical improvement.
The systematic review confirms the high prevalence of Te deficiency in HIV-infected men, particularly when fT has been considered.
Correlation studies between classic lipid profiles and lipidomic results showed different information.
For patients with NSTI undergoing surgical management, persistent organ dysfunction at 14 days, strongly predicts higher resource utilization, poor discharge disposition, and higher long-term mortality.
Nivolumab is likely to be cost-effective for the treatment of patients with advanced NSCLC following platinum-based chemotherapy in the United States.
No cases of IBD were observed and rates of GI SAEs were low through 4 years of treatment with guselkumab in two large trials of patients with psoriasis.
To this end, we investigated the sequence diversity of the spike protein and monitored emergence of virus variants in SARS-COV-2 isolates found in COVID-19 patients treated with the two-antibody combination REGEN-COV, as well...
The optimal intervention should be targeted to cognitive decline in the early stages of dementia.
TCZ in early SSc-associated ILD with progressive skin disease stabilized FVC% over 48 weeks, independent of the extent of radiographically evident QILD.
When examined as a continuous variable, baseline biomarker levels did not modify the association between progesterone treatment and neurological outcome ( p of interaction term >0.39 for all biomarkers).
In an updated analysis from the phase III MONALEESA‐3 trial with more than 4.5 years of follow‐up, ribociclib plus fulvestrant maintained a significant overall survival benefit compared with fulvestrant alone in postmenopausal...
Female patients had significantly higher incidences of grade 2+ IMAEs than male patients.
These findings complement the sustained and significant improvement in progression-free survival observed with D-Rd and supports its use in patients with RRMM.
MOB-015 is a treatment option for onychomycosis with an adverse event profile similar to vehicle.
With more than 6 years of follow‐up in the phase III PALOMA‐3 trial, the addition of palbociclib to fulvestrant maintained a significant survival benefit compared with fulvestrant alone in patients with HR‐positive,...
These population PK analyses characterize activity-time profiles for rFVIIIFc among children and adult subjects.
No notable AEs occurred because of the UPA treatment, and the incidence of AEs in the UPA group was comparable with that of AEs in the LEU group.
Neither drug modified the frequencies of IL-17A + IL ‒ 17F + / - CD4 + or CD8 + T cells.
Alpelisib plus fulvestrant provides long‐term disease control in patients with endocrine‐resistant, HR‐positive, HER2‐negative, PIK3CA‐mutated advanced breast cancer, according to an updated analysis from the SOLAR‐1 and X2101...
In this study, no differences were found in the bowel or urinary symptoms between the adjuvant and neoadjuvant approach.
We determined if the results for the Indian patients were in-line with the results of overall population.
As in patients with GC, FTD/TPI showed an efficacy benefit in patients with GEJC in the TAGS trial, along with demonstrating a manageable safety profile.
Conclusion: This post hoc analysis supports the efficacy and tolerability of ceftobiprole in East Asian patients.
The incidences of nausea and vomiting were significantly lower in the FC treatment groups than in the SF group.
OCT 0.1% mouthwash inhibits plaque formation over 5 days.
Plasma ruxolitinib concentrations after treatment with applied to the skin ruxolitinib cream in patients with up to 20% BSA affected by AD are not expected to lead to systemic plasma concentrations that may be associated with...
Only marginal covariate effects were observed, and thus no dose adjustments are deemed necessary for FF, UMEC, or.
The addition of GO had no impact in these molecular clusters.
Higher SBPV and PPV were associated with greater risk of incident frailty.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
